Media Advisory - PS Dabrusin to Make an Electric Vehicle Infrastructure Announcement
OTTAWA, ON, Jan. 24, 2022 /CNW/ - Julie Dabrusin, Parliamentary Secretary to the Minister of Natural Resources and to the Minister of Environment and Climate Change, on behalf of the Honourable Jonathan Wilkinson, Minister of Natural Resources, will make a virtual announcement to support electric vehicle charging infrastructure in Ontario.
A media availability will follow.
Date:
January 25, 2022
Time:
1 p.m. EST
Location:
This virtual event will be held using the Zoom platform.
Accredited media are asked to pre-register to participate.
Note: To help ensure optimal sound quality, journalists are encouraged to use a microphone (headphones/headset) or, when possible, a landline, and to avoid using speaker mode if queuing up for questions.
Bristol Myers Squibb today announced the Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS) in unresectable, locally advanced stage III non-small cell lung cancer (NSCLC). CheckMate -73L evaluated...
Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung...
Merrimack Pharmaceuticals, Inc. ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that announcement, the Board of Directors declared a...
LivePerson, Inc. is providing confirmatory notice, in compliance with the requirements of Nasdaq Listing Rule 5635(c)(4), of recent grants of equity-based incentive awards that LivePerson made under the LivePerson Inc. 2018 Inducement Plan (the...
Getaround ("Getaround'' or "the Company"), the world's first connected carsharing marketplace, today announced three new additions to its Board of Directors. Nikul Patel, Neil Savage and Qais Sharif effective May 6, 2024. They will join existing...
Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2024 and provided an...
